Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

NCT04602533 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Limited Stage

Interventions

DRUG: Durvalumab
DRUG: standard of care

Sponsor

Michael Hopp

Collaborators

[object Object]